FDA Warning Letter Blasts Mylan’s Continued Lax Impurity Controls for APIs
Company Needs To Beef Up Equipment Cleaning And Monitoring Of Recovered Solvents For Impurities
Concerned about another possible nitrosamine scare, US FDA warning letter to Mylan focuses on firm’s failure to control contamination risks of its APIs and its inadequate testing of reused solvents.
